Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data

Six-month therapy of CGRP monoclonal antibodies in real-world clinical practice: an interim analysis of efficacy and safety data

Introduction. Migraine is one of the most common disabling neurological disorders. Recently developed monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor are the first targeted medication for preventive therapy of both episodic and chronic migraine. They have been thoroug...

Full description

Bibliographic Details
Main Authors: N. V. Vashchenko, A. M. Uzhakhov, M. V. Bogorodskaya, D. Z. Korobkova, Ju. E. Azimova, K. V. Skorobogatykh
Format: Article
Language:Russian
Published: Remedium Group LLC 2022-01-01
Series:Медицинский совет
Subjects:
migraine
preventive therapy
cgrp
monoclonal antibodies
erenumab
Online Access:https://www.med-sovet.pro/jour/article/view/6608

Similar Items

Similar Items